S

ST Pharm Co Ltd
KOSDAQ:237690

Watchlist Manager
ST Pharm Co Ltd
KOSDAQ:237690
Watchlist
Price: 86 100 KRW 0.94% Market Closed
Market Cap: 1.7T KRW
Have any thoughts about
ST Pharm Co Ltd?
Write Note

ST Pharm Co Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ST Pharm Co Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
S
ST Pharm Co Ltd
KOSDAQ:237690
Total Equity
â‚©384.6B
CAGR 3-Years
8%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Total Equity
â‚©10.6T
CAGR 3-Years
29%
CAGR 5-Years
21%
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Total Equity
â‚©101.6B
CAGR 3-Years
24%
CAGR 5-Years
38%
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Total Equity
â‚©54.9B
CAGR 3-Years
0%
CAGR 5-Years
36%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Total Equity
â‚©148.2B
CAGR 3-Years
-15%
CAGR 5-Years
5%
CAGR 10-Years
27%
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Total Equity
-â‚©20.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ST Pharm Co Ltd
Glance View

Market Cap
1.6T KRW
Industry
Life Sciences Tools & Services

Nestled in the bustling metropolis of Seoul, South Korea, ST Pharm Co Ltd. operates as a dynamic player within the global pharmaceutical industry. Established initially to meet the burgeoning demands of the local pharmaceutical market, the company has slowly carved out a niche for itself in the global arena. With a deft focus on the development and manufacture of active pharmaceutical ingredients (APIs), ST Pharm now sets its sights on becoming a central figure in the synthesis of high-value APIs used in therapies including antivirals and oncology treatments. This focus isn't merely driven by opportunity; it's underpinned by a dedicated commitment to cutting-edge research and development. The company has invested heavily in state-of-the-art facilities and nurtures a team of seasoned scientists who remain at the forefront of innovation. ST Pharm makes its revenue by mastering the art of efficient and reliable API production. By optimizing their production processes, they can offer a competitive edge—delivering high-quality products at scale. The company isn't solely interested in the immediate gains of API manufacture; it also sees potential in providing customized solutions to its diverse clientele, which spans multinational pharmaceutical giants to nimble biotech startups. Partnerships and collaborations have become crucial strategies for ST Pharm, facilitating an exchange of innovation and expertise that keeps them relevant and forward-thinking. In this regard, their business model elegantly balances between standardized API production and bespoke chemical solutions, ensuring a steady revenue stream while opening doors to future advancements in pharmaceutical science.

Intrinsic Value
103 228.82 KRW
Undervaluation 17%
Intrinsic Value
Price
S

See Also

What is ST Pharm Co Ltd's Total Equity?
Total Equity
384.6B KRW

Based on the financial report for Sep 30, 2024, ST Pharm Co Ltd's Total Equity amounts to 384.6B KRW.

What is ST Pharm Co Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
4%

Over the last year, the Total Equity growth was 2%. The average annual Total Equity growth rates for ST Pharm Co Ltd have been 8% over the past three years , 4% over the past five years .

Back to Top